Drugs With Fewest Side-Effects for Treating Irritable Bowel Syndrome Identified, Study Suggests - ScienceDaily
Cedars-Sinai researchers have determined that two prevalent drug therapies -- rifaximin and lubiprostone -- offer some of the best options for treating irritable bowel syndrome, a widespread disorder that affects up to one in five Americans. The findings, based on an analysis of more than two dozen large-scale clinical trials, are contained in a peer-reviewed study published online by The American Journal of Medicine and set to appear in the publication's April print edition.
Besides Cedars-Sinai, other centers participating in the research included the School of Medicine at Texas Tech University's Health Sciences Center; the UCLA Department of Medicine; Beth Israel Deaconess Medical Center; and Harvard Medical School.
Read the full story >>
The Texas Tech University Health Sciences Center (TTUHSC) Graduate School of Biomedical Sciences hosted its 34th Annual Student Research Week March 8-11.
The National Cancer Institute awarded a five-year, $1.9 million grant to C. Patrick Reynolds, M.D., Ph.D., director for the School of Medicine Cancer Center at TTUHSC.
The Willed Body Program has served West Texas since 1972 and is the foundation upon which the TTUHSC Institute of Anatomical Sciences is built.
The Texas Tech University Health Sciences Center (TTUHSC) recently hosted traditional commencement ceremonies for its 1,595-member Class of 2022.